Ionis Pharmaceuticals (IONS) Competitors $38.76 +0.37 (+0.96%) (As of 11/1/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends IONS vs. JAZZ, BHVN, RARE, PRGO, BHC, UTHR, BMRN, EXAS, INCY, and NBIXShould you be buying Ionis Pharmaceuticals stock or one of its competitors? The main competitors of Ionis Pharmaceuticals include Jazz Pharmaceuticals (JAZZ), Biohaven (BHVN), Ultragenyx Pharmaceutical (RARE), Perrigo (PRGO), Bausch Health Companies (BHC), United Therapeutics (UTHR), BioMarin Pharmaceutical (BMRN), Exact Sciences (EXAS), Incyte (INCY), and Neurocrine Biosciences (NBIX). These companies are all part of the "medical" sector. Ionis Pharmaceuticals vs. Jazz Pharmaceuticals Biohaven Ultragenyx Pharmaceutical Perrigo Bausch Health Companies United Therapeutics BioMarin Pharmaceutical Exact Sciences Incyte Neurocrine Biosciences Jazz Pharmaceuticals (NASDAQ:JAZZ) and Ionis Pharmaceuticals (NASDAQ:IONS) are both mid-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, valuation, institutional ownership, earnings, analyst recommendations, dividends, community ranking, profitability and media sentiment. Is JAZZ or IONS more profitable? Jazz Pharmaceuticals has a net margin of 10.10% compared to Ionis Pharmaceuticals' net margin of -44.90%. Jazz Pharmaceuticals' return on equity of 28.65% beat Ionis Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Jazz Pharmaceuticals10.10% 28.65% 9.29% Ionis Pharmaceuticals -44.90%-115.66%-12.83% Does the MarketBeat Community favor JAZZ or IONS? Jazz Pharmaceuticals received 425 more outperform votes than Ionis Pharmaceuticals when rated by MarketBeat users. Likewise, 80.62% of users gave Jazz Pharmaceuticals an outperform vote while only 60.21% of users gave Ionis Pharmaceuticals an outperform vote. CompanyUnderperformOutperformJazz PharmaceuticalsOutperform Votes111580.62% Underperform Votes26819.38%Ionis PharmaceuticalsOutperform Votes69060.21% Underperform Votes45639.79% Which has stronger earnings & valuation, JAZZ or IONS? Jazz Pharmaceuticals has higher revenue and earnings than Ionis Pharmaceuticals. Ionis Pharmaceuticals is trading at a lower price-to-earnings ratio than Jazz Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioJazz Pharmaceuticals$3.83B1.78$414.83M$5.8218.98Ionis Pharmaceuticals$788M7.19-$366.29M-$2.52-15.38 Do insiders and institutionals have more ownership in JAZZ or IONS? 89.1% of Jazz Pharmaceuticals shares are held by institutional investors. Comparatively, 93.9% of Ionis Pharmaceuticals shares are held by institutional investors. 4.2% of Jazz Pharmaceuticals shares are held by insiders. Comparatively, 2.7% of Ionis Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Do analysts recommend JAZZ or IONS? Jazz Pharmaceuticals presently has a consensus price target of $173.43, suggesting a potential upside of 57.02%. Ionis Pharmaceuticals has a consensus price target of $60.28, suggesting a potential upside of 55.52%. Given Jazz Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Jazz Pharmaceuticals is more favorable than Ionis Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Jazz Pharmaceuticals 0 Sell rating(s) 3 Hold rating(s) 11 Buy rating(s) 0 Strong Buy rating(s) 2.79Ionis Pharmaceuticals 1 Sell rating(s) 6 Hold rating(s) 12 Buy rating(s) 1 Strong Buy rating(s) 2.65 Does the media favor JAZZ or IONS? In the previous week, Jazz Pharmaceuticals had 2 more articles in the media than Ionis Pharmaceuticals. MarketBeat recorded 9 mentions for Jazz Pharmaceuticals and 7 mentions for Ionis Pharmaceuticals. Jazz Pharmaceuticals' average media sentiment score of 0.79 beat Ionis Pharmaceuticals' score of 0.69 indicating that Jazz Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Jazz Pharmaceuticals 4 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ionis Pharmaceuticals 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility and risk, JAZZ or IONS? Jazz Pharmaceuticals has a beta of 0.57, suggesting that its share price is 43% less volatile than the S&P 500. Comparatively, Ionis Pharmaceuticals has a beta of 0.38, suggesting that its share price is 62% less volatile than the S&P 500. SummaryJazz Pharmaceuticals beats Ionis Pharmaceuticals on 15 of the 19 factors compared between the two stocks. Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here Get Ionis Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for IONS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IONS vs. The Competition Export to ExcelMetricIonis PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.67B$7.02B$5.40B$8.53BDividend YieldN/A7.96%5.13%4.14%P/E Ratio-15.389.74115.4815.20Price / Sales7.19381.431,483.2092.69Price / CashN/A47.3339.6534.06Price / Book14.365.324.665.02Net Income-$366.29M$153.56M$119.06M$225.46M7 Day Performance-1.10%0.12%0.80%0.37%1 Month Performance-1.57%15.23%5.66%3.57%1 Year Performance-11.37%41.16%36.76%29.43% Ionis Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IONSIonis Pharmaceuticals4.2376 of 5 stars$38.76+1.0%$60.28+55.5%-14.4%$5.67B$788M-15.38800Upcoming EarningsShort Interest ↓News CoverageJAZZJazz Pharmaceuticals4.7869 of 5 stars$109.55+1.4%$173.43+58.3%-13.3%$6.76B$3.83B18.822,800Upcoming EarningsBHVNBiohaven2.6476 of 5 stars$52.84+0.9%$61.92+17.2%+72.5%$4.67B$462.51M-5.77239RAREUltragenyx Pharmaceutical4.1907 of 5 stars$53.82-1.8%$85.08+58.1%+41.5%$4.47B$481.30M-7.371,276Upcoming EarningsPRGOPerrigo4.9062 of 5 stars$25.09+0.0%$37.00+47.5%-6.9%$3.42B$4.43B-27.279,140Upcoming EarningsDividend AnnouncementBHCBausch Health Companies3.925 of 5 stars$8.04-1.0%$7.33-8.8%+38.1%$2.90B$9.20B-6.2820,270Earnings ReportAnalyst ForecastOptions VolumeNews CoverageUTHRUnited Therapeutics4.5029 of 5 stars$348.65-0.4%$361.33+3.6%+66.9%$15.46B$2.62B16.021,168Earnings ReportAnalyst ForecastInsider SellingNews CoveragePositive NewsBMRNBioMarin Pharmaceutical4.9752 of 5 stars$69.73-0.9%$96.40+38.2%-20.7%$13.24B$2.59B52.433,401Earnings ReportAnalyst ForecastShort Interest ↑Analyst RevisionNews CoverageEXASExact Sciences4.2461 of 5 stars$69.11-1.6%$78.38+13.4%+9.9%$13.04B$2.50B-71.996,600Upcoming EarningsAnalyst ForecastShort Interest ↑INCYIncyte4.1272 of 5 stars$65.07-0.3%$73.42+12.8%+40.0%$12.53B$3.70B180.752,524Earnings ReportAnalyst UpgradeShort Interest ↑News CoverageNBIXNeurocrine Biosciences4.9511 of 5 stars$116.08+0.5%$163.91+41.2%+9.6%$11.72B$1.89B35.071,400Earnings ReportAnalyst ForecastAnalyst RevisionNews Coverage Related Companies and Tools Related Companies JAZZ Competitors BHVN Competitors RARE Competitors PRGO Competitors BHC Competitors UTHR Competitors BMRN Competitors EXAS Competitors INCY Competitors NBIX Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:IONS) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredNvidia warning urgentI thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredNothing can stop this gold rallyAfter what's felt like nearly a decade of disappointing gains, gold is stronger than ever and continues to hit...Stansberry Research | SponsoredWall St. Legend: Millions of Americans About to Fall Out of the 1%Wall Street insider reveals the financial tidal wave about to knock millions of Americans out of the One Perce...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ionis Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ionis Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
